By creator to www.galvnews.com
HORSHAM, Pa.–(BUSINESS WIRE)–Oct 20, 2020–
Palladio Biosciences, Inc. (Palladio), a privately-owned, medical stage biopharmaceutical firm growing medicines for orphan illnesses of the kidney, introduced at the moment the outcomes of a research that investigated the usage of lixivaptan in a affected person with autosomal dominant polycystic kidney illness (ADPKD) who couldn’t tolerate a unique vasopressin V2 receptor antagonist, tolvaptan. The presentation will probably be made as an ePoster throughout the American Society of Nephrology’s Kidney Week 2020. The convention is being held as a completely digital assembly, October 22-25.
The presentation will embrace the outcomes of greater than 12 months of protected therapy with lixivaptan on this research, which was carried out as an expanded entry medical research beneath an IND. The affected person was experiencing vital high quality of life points as a consequence of her ADPKD, which had initially improved with tolvaptan therapy. Sadly, she developed clinically-meaningful alanine aminotransferase (ALT) elevations, an indication of liver toxicity, on every of three sequential therapy makes an attempt with tolvaptan. This supplied the idea to provoke lixivaptan therapy as an alternative.
“The affected person has not skilled any elevations of ALT or different chemistry assessments throughout therapy with lixivaptan. These outcomes, plus different medical information we are going to current throughout the convention, spotlight the liver security profile of lixivaptan in sufferers at excessive threat for growing liver toxicity,” stated Dr Neil H Shusterman, Chief Medical Officer of Palladio. “To additional research this potential, we’re presently enrolling sufferers in a bigger research (PA-ADPKD-303: The ALERT Study during which ADPKD sufferers who beforehand discontinued tolvaptan due to liver chemistry elevations will probably be handled with lixivaptan.”
Particulars for the poster summary are listed beneath. The ePoster might be seen on-demand beginning October 22 at 10:00 a.m. EDT. Digital convention options embrace an interactive interface and particular communication instruments accessible by Kidney Week registration and login. These instruments embrace a dialogue board for every ePoster presentation for Kidney Week individuals to have interaction in a Q&A session with presenters. The presentation might be accessed on-line on the convention web site with the related hyperlink.
- Use of Lixivaptan in a Affected person with Autosomal Dominant Polycystic Kidney Illness (ADPKD) Who Beforehand Skilled Liver Toxicity with Tolvaptan
Poster Quantity: PO1545
Presentation date/time: Thursday, October 22, 10:00 a.m. EDT
About Palladio Biosciences, Inc.
Palladio Biosciences is a privately-held, medical stage biopharmaceutical firm growing medicines for orphan illnesses of the kidney. Palladio is growing its lead drug, lixivaptan, for autosomal dominant polycystic kidney illness (ADPKD), an orphan kidney illness for which there are restricted therapy choices. Lixivaptan is a potent, selective vasopressin V2 receptor antagonist, a mechanism of motion that has medical proof of idea to gradual kidney operate decline in adults vulnerable to quickly progressing ADPKD. Lixivaptan is for investigational use solely. For extra data, please go to Palladio Biosciences.
Polycystic Kidney Illness (PKD) Key Information and Figures
PKD is an inherited genetic illness that impacts as much as 600,000 individuals in america and hundreds of thousands globally. It’s estimated that roughly 140,000 individuals in america have been recognized with ADPKD, the most typical sort of PKD. An individual with ADPKD has a 50 p.c likelihood of passing the illness on to every of his or her kids. The illness is characterised by uncontrolled progress of fluid-filled cysts within the kidney, which might every develop to be as massive as a soccer. Signs usually embrace kidney infections and ache. The continued enlargement of cysts and alternative of regular kidney tissue causes irreversible lack of renal operate. Yearly there are roughly 2,500 new PKD sufferers in america who require dialysis or a kidney transplant, making PKD the fourth main explanation for kidney failure. There is no such thing as a treatment for PKD.
View supply model on businesswire.com:https://www.businesswire.com/news/home/20201020005214/en/
CONTACT: Linda Hogan
Palladio Biosciences, Inc.
KEYWORD: UNITED STATES NORTH AMERICA PENNSYLVANIA
INDUSTRY KEYWORD: HEALTH OTHER HEALTH OTHER SCIENCE CLINICAL TRIALS SCIENCE PHARMACEUTICAL BIOTECHNOLOGY
SOURCE: Palladio Biosciences, Inc.
Copyright Enterprise Wire 2020.
PUB: 10/20/2020 10:17 AM/DISC: 10/20/2020 10:17 AM
Copyright Enterprise Wire 2020.
— to www.galvnews.com